188 related articles for article (PubMed ID: 29574193)
41. A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.
Wentink MQ; Broxterman HJ; Lam SW; Boven E; Walraven M; Griffioen AW; Pili R; van der Vliet HJ; de Gruijl TD; Verheul HM
Br J Cancer; 2016 Oct; 115(8):940-948. PubMed ID: 27575850
[TBL] [Abstract][Full Text] [Related]
42. Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR
Byrd RA; Owens RA; Blackbourne JL; Coutant DE; Farmen MW; Michael MD; Moyers JS; Schultze AE; Sievert MK; Tripathi NK; Vahle JL
Regul Toxicol Pharmacol; 2017 Aug; 88():56-65. PubMed ID: 28526658
[TBL] [Abstract][Full Text] [Related]
43. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
[TBL] [Abstract][Full Text] [Related]
44. Preclinical evaluation of
Kameswaran M; Sarma HD; Dash A
Appl Radiat Isot; 2017 May; 123():109-113. PubMed ID: 28260607
[TBL] [Abstract][Full Text] [Related]
45. Epitope Mapping for a Preclinical Bevacizumab (Avastin) Biosimilar on an Extended Construct of Vascular Endothelial Growth Factor A Using Millisecond Hydrogen-Deuterium Exchange Mass Spectrometry.
Brown KA; Lento C; Rajendran S; Dowd J; Wilson DJ
Biochemistry; 2020 Aug; 59(30):2776-2781. PubMed ID: 32672953
[TBL] [Abstract][Full Text] [Related]
46. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
47. The natural compound codonolactone impairs tumor induced angiogenesis by downregulating BMP signaling in endothelial cells.
Wang S; Cai R; Ma J; Liu T; Ke X; Lu H; Fu J
Phytomedicine; 2015 Oct; 22(11):1017-26. PubMed ID: 26407944
[TBL] [Abstract][Full Text] [Related]
48. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
[TBL] [Abstract][Full Text] [Related]
49. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
[TBL] [Abstract][Full Text] [Related]
50. Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar.
Goyal P; Iyer J; Adhikary L; Vats B; Kabadi P; Pai H; Ranayhossaini D; Gouda S; Subbarao M; Mehta G; Saha A; Bera A; Sahu A; Kaur M; Singh A; Marwah A; Reddy Moole PK; Smith J; Melarkode R; Ullanat R
Future Med Chem; 2021 Sep; 13(18):1531-1557. PubMed ID: 34289749
[No Abstract] [Full Text] [Related]
51. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
52. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
53. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
[TBL] [Abstract][Full Text] [Related]
54. Bevacizumab in advanced lung cancer: state of the art.
Assoun S; Brosseau S; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2515-2535. PubMed ID: 28812378
[TBL] [Abstract][Full Text] [Related]
55. Bevacizumab-induced hypertension: pathogenesis and management.
Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
[TBL] [Abstract][Full Text] [Related]
56. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.
Rosen LS; Jacobs IA; Burkes RL
Target Oncol; 2017 Oct; 12(5):599-610. PubMed ID: 28801849
[TBL] [Abstract][Full Text] [Related]
57. Direct Effects of Bevacizumab on Rat Conjunctival Fibroblast.
Cheng G; Xiang H; Yang G; Ma J; Zhao J
Cell Biochem Biophys; 2015 Sep; 73(1):45-50. PubMed ID: 25656769
[TBL] [Abstract][Full Text] [Related]
58. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Thomas M; Thatcher N; Goldschmidt J; Ohe Y; McBride HJ; Hanes V
Immunotherapy; 2019 Oct; 11(15):1337-1351. PubMed ID: 31556762
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
Miyake T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ogasawara K; Ohji M
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
[TBL] [Abstract][Full Text] [Related]
60. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
Thaler S; Fiedorowicz M; Choragiewicz TJ; Bolz S; Tura A; Henke-Fahle S; Yoeruek E; Zrenner E; Bartz-Schmidt KU; Ziemssen F; Schuettauf F
Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]